Trials / Completed
CompletedNCT02584855
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 394 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2015-09-14
- Primary completion
- 2018-10-30
- Completion
- 2018-10-30
- First posted
- 2015-10-23
- Last updated
- 2019-11-15
- Results posted
- 2019-11-15
Locations
106 sites across 12 countries: United States, Bulgaria, Czechia, Estonia, Mexico, Poland, Russia, Slovakia, South Africa, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT02584855. Inclusion in this directory is not an endorsement.